Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050143 | 0.95 | MAOA (0.54) | SIGMAR1TMEM97MAOACHRM2LTA4H | |
| SCHEMBL3051170 | 0.91 | KMT2A (0.50) | SIGMAR1TMEM97MAOACHRM2MEN1 | |
| SCHEMBL30090684 | 0.85 | SIGMAR1 (0.69) | SIGMAR1TMEM97MAOACHRM2MEN1 | |
| SCHEMBL1443953 | 0.79 | MAOA (0.64) | SIGMAR1TMEM97MAOACHRM2MEN1 | |
| SCHEMBL3051182 | 0.78 | ALDH1A1 (0.50) | SIGMAR1TMEM97LTA4HKMT2A | |
| SCHEMBL3047704 | 0.78 | SIGMAR1 (0.57) | SIGMAR1TMEM97MAOALTA4H | |
| SCHEMBL3050138 | 0.78 | SIGMAR1 (0.62) | SIGMAR1MAOALTA4HMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL21493579 | 0.77 | MAOA (0.62) | SIGMAR1TMEM97MAOACHRM2MEN1 | |
| SCHEMBL10941196 | 0.76 | SIGMAR1 (0.66) | SIGMAR1TMEM97MAOACHRM2MEN1 | |
| SCHEMBL16151778 | 0.76 | CHRM2 (0.63) | SIGMAR1TMEM97MAOACHRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | claimed |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | VISKOV CHRISTIAN | 2010-07-08 | — | — | US | disclosed |
| US-7678766-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2010-03-16 | — | — | US | disclosed |
| EP-1098903-B1 | METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA SA (FR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070213260-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. | 2007-09-13 | — | — | US | disclosed |
| US-7226905-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2007-06-05 | — | — | US | disclosed |
| EP-0979244-B1 | NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-03-02 | — | — | EP | disclosed |
| EP-1040121-B1 | NOVEL METHOD FOR PREPARING CYLOSPORIN DERIVATIVES | AVENTIS PHARMA (FR) | 2004-07-21 | — | — | EP | disclosed |
| EP-0948527-B1 | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | disclosed |
| EP-1098903-A1 | NOVEL METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-05-16 | — | — | EP | disclosed |
| WO-1999067280-A1 | NOVEL METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 1999-12-29 | — | — | WO | disclosed |
| EP-0951474-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998028330-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213260-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | SIGMAR1 1115/4885TMEM97 767/4885MAOA 2810/4885 |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | SIGMAR1 1115/4885TMEM97 767/4885MAOA 2810/4885 |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | MGMT, MALT1, CHP1 | SIGMAR1 787/4885TMEM97 518/4885MAOA 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.